Venetoclax + Azacitidine
ApprovedActive 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia (AML)
Conditions
Acute Myeloid Leukemia (AML)
Trial Timeline
Jan 6, 2022 → Mar 1, 2026
NCT ID
NCT05144243About Venetoclax + Azacitidine
Venetoclax + Azacitidine is a approved stage product being developed by AbbVie for Acute Myeloid Leukemia (AML). The current trial status is active. This product is registered under clinical trial identifier NCT05144243. Target conditions include Acute Myeloid Leukemia (AML).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05144243 | Approved | Active |
| NCT04161885 | Phase 3 | Terminated |
| NCT02966782 | Phase 1 | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia (AML)